2021-3-1 · Hepatocellular carcinoma (HCC) is one of the most common malignancies and its treatment is limited. With the understanding of key genes and signaling pathways in the occurrence and development of HCC targeted drugs with high selectivity and low toxicity have been developed continuously bringing a variety of options for the treatment of advanced HCC.
Clinical significance of SLP-2 in hepatocellular carcinoma tissues and its regulation in cancer cell proliferation migration and EMT. Onco Targets Ther. 2017 Sep 2010 4665-4673. doi 10.2147/OTT.S144638. eCollection 2017.
2019-6-22 · Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles. Xiaoou Wang Department of Clinical Laboratory The Second Affiliated Hospital and Yuying Children s Hospital of Wenzhou Medical University Wenzhou China.
2021-3-1 · Hepatocellular carcinoma (HCC) is one of the most common malignancies and its treatment is limited. With the understanding of key genes and signaling pathways in the occurrence and development of HCC targeted drugs with high selectivity and low toxicity have been developed continuously bringing a variety of options for the treatment of advanced HCC.
2020-4-20 · Liver hepatocellular carcinoma is a comprehensive disease with high mortality and morbidity. 1 It has been reported that CSCs play a key role in tumor development. 22 Thus therapeutic targeting of LIHC stem cells is of great importance. CSCs possess strong drug resistance and metastasis characteristics and the regulatory mechanism of stem
2021-7-2 · Guo W. et al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin. Cancer Res. 20
2021-7-13 · Objective Hepatocellular carcinoma (HCC) tumour microenvironment (TME) is highly complex with diverse cellular components organising into various functional units cellular neighbourhoods (CNs). And we wanted to define CN of HCC while preserving the TME architecture based on which potential targets for novel immunotherapy could be identified. Design A highly
2019-3-22 · 1. Onco Targets Ther. 2019 Mar 2212 2149-2157. doi 10.2147/OTT.S197326. eCollection 2019. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.
The Journal of Hepatocellular Carcinoma is an international peer-reviewed open access journal. The journal welcomes original research manuscripts reviews clinical trial reports expert opinions and commentaries relating to all aspects of HCC spanning from basic laboratory research through to clinical and translational research.
2006-11-10 · Human hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer death with prevalent areas in Asia and sub-Saharan Africa. ( 9 ) Although recent studies suggested increase of HCC incidence in western countries >80 of the HCC cases occurred in above endemic areas are owing to exposure of
2016-1-14 · 1. Onco Targets Ther. 2016 Jan 149 325-33. doi 10.2147/OTT.S95985. eCollection 2016. Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma.
2021-3-25 · Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide but has the second highest mortality and thus among the common cancers HCC
2016-4-14 · Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and has well-known risk factors including cirrhosis and viral hepatitis. Here Llovet and colleagues discuss the
HepatoCellular Carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide. NEXAVAR® was approved by the FDA in 2007 for the treatment of unresectable HepatoCellular Carcinoma (HCC). Patients with advanced HCC who progress on NEXAVAR® have a poor prognosis with limited treatment options.
2016-1-14 · 1. Onco Targets Ther. 2016 Jan 149 325-33. doi 10.2147/OTT.S95985. eCollection 2016. Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma.
2021-3-25 · Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide but has the second highest mortality and thus among the common cancers HCC
2021-5-1 · Typical hepatocellular features such as bile production Mallory hyaline and steatosis can be observed. Histochemical stains like reticulin demonstrate loss or fragmentation of the reticulin network and help support a diagnosis of HCC whereas demonstration of mucin with mucicarmine stain supports intrahepatic cholangiocarcinoma (CCA) or
2021-3-1 · Hepatocellular carcinoma (HCC) is one of the most common malignancies and its treatment is limited. With the understanding of key genes and signaling pathways in the occurrence and development of HCC targeted drugs with high selectivity and low toxicity have been developed continuously bringing a variety of options for the treatment of advanced HCC.
2020-10-15 · Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. provide novel targets for therapeutic interventions in HCC and open avenues for identifying similar paradigms in other cancers and disease. Graphical Abstract.
2019-3-22 · 1. Onco Targets Ther. 2019 Mar 2212 2149-2157. doi 10.2147/OTT.S197326. eCollection 2019. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.
Onco Therapeutics Editor-in-Chief Benjamin Bonavida. From Targets to Targeted Therapies in Hepatocellular Carcinoma. pages 145-194. DOI 10.1615/ForumImmunDisTher.2015013982. Get access. Melchiorre Cervello Prognosis in advanced hepatocellular carcinoma (HCC) remains poor despite the great improvement in the knowledge of the
2020-4-20 · Liver hepatocellular carcinoma is a comprehensive disease with high mortality and morbidity. 1 It has been reported that CSCs play a key role in tumor development. 22 Thus therapeutic targeting of LIHC stem cells is of great importance. CSCs possess strong drug resistance and metastasis characteristics and the regulatory mechanism of stem
Abstract. The OncoDB.HCC (http //oncodb.hcc.ibms.sinica.edu.tw) is based on physical maps of rodent and human genomes containing quantitative trait loci of rodent HCC models and various human HCC somatic aberrations including chromosomal data from loss of heterozygosity and comparative genome hybridization analyses altered expression of genes from
2016-1-14 · Onco Targets Ther. 2016 Jan 149 325-33. doi 10.2147/OTT.S95985. eCollection 2016. Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma. Deng L(1) Yang J(2) Chen H(3)
2019-11-27 · Luo X. et al. MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma. Onco Targets Ther. 8 3159–3167 (2015).
2019-10-14 · Xie H. et al. A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma. Onco. Targets Ther. 11 3257–3265 (2018).
2019-3-22 · Onco Targets Ther. 2019 Mar 2212 2149-2157. doi 10.2147/OTT.S197326. eCollection 2019. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. Zhang H(1) Zhang Z(2) Gao L(3) Qiao Z(3) Yu M(4) Yu B(1)(3) Yang T(1).
2006-11-10 · Human hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer death with prevalent areas in Asia and sub-Saharan Africa. ( 9 ) Although recent studies suggested increase of HCC incidence in western countries >80 of the HCC cases occurred in above endemic areas are owing to exposure of
Onco Targets Ther 20158 2129-37. Kong J Shen S Wang W. Synchronous hepatectomy and splenectomy vs hepatectomy for selected patients with hepatocellular carcinoma and clinically significant portal hypertension A systematic review and meta-analysis. J
2019-8-19 · Onco Targets Ther. 201811 3407-13 49. Abou-Alfa GK Puig O Daniele B. et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 201665 289-95 50. Cerrito L Ponziani FR Garcovich M. et al. Regorafenib a promising treatment for hepatocellular carcinoma.
The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection a systematic review and meta-analysis. Onco Targets Ther. 2017 Nov 1010 5363-5375. doi 10.2147/OTT.S150281. eCollection 2017.
2019-11-27 · Luo X. et al. MicroRNA-328 enhances cellular motility through posttranscriptional regulation of PTPRJ in human hepatocellular carcinoma. Onco Targets Ther. 8 3159–3167 (2015).
2021-5-1 · Typical hepatocellular features such as bile production Mallory hyaline and steatosis can be observed. Histochemical stains like reticulin demonstrate loss or fragmentation of the reticulin network and help support a diagnosis of HCC whereas demonstration of mucin with mucicarmine stain supports intrahepatic cholangiocarcinoma (CCA) or
2020-11-6 · 3. Casadei Gardini A Puzzoni M Montagnani F et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma design development potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all phase III trials. Onco Targets Ther. 201912 2981-2988. doi 10.2147/OTT. S192572
2019-8-29 · Onco Targets Ther. 2019 Aug 2912 7045-7054. doi 10.2147/OTT.S213705. eCollection 2019. MicroRNA-3651 promotes the growth and invasion of hepatocellular carcinoma cells by targeting PTEN. Zhao X(#)(1) Song Q(#)(2) Miao G(#)(3) Zhu X(1).
2006-11-10 · OncoDB.HCC an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci Wen-Hui Su 1 5Chuan-Chuan Chao 5Shiou-Hwei Yeh 2Ding-Shinn Chen 3 4Pei-Jer Chen 3 4and Yuh-Shan Jou1 5 1Graduate Institute of Life Sciences National Defense Medical Center National Defense University Taipei 114 Taiwan
Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. provide novel targets for therapeutic interventions in HCC and open avenues for identifying similar paradigms in other cancers and disease. Graphical Abstract.
2020-10-15 · Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. provide novel targets for therapeutic interventions in HCC and open avenues for identifying similar paradigms in other cancers and disease. Graphical Abstract.
2021-4-5 · Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. A first-line standard of care sorafenib results in median overall survival of 12 months in patients with Child-Pugh class A disease and 6 months in patients with Child-Pugh class B disease with objective response rates (ORRs) not exceeding 19 .
2017-4-24 · Molecular targeted therapy for hepatocellular carcinoma Current and future Jung Woo Shin Young-Hwa Chung improved knowledge of the onco-genic processes and signaling pathways that regulate tumor cell proliferation differentiation angiogenesis which targets the lipid products of PI3K for dephosphorylation 21 .
2020-11-6 · 3. Casadei Gardini A Puzzoni M Montagnani F et al. Profile of lenvatinib in the treatment of hepatocellular carcinoma design development potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all phase III trials. Onco Targets Ther. 201912 2981-2988. doi 10.2147/OTT. S192572
BQ+ Medical not only produce components for manufacturers all over the world, but also provide private label manufacturing for leading brand distributors in different countries.
8,Cheye Road,Songjiang District,Shanghai 201611 China.
Tel: 86-021-57743953
Email: [email protected]
Copyright © BQ PLUS MEDICAL CO., LTDSitemap | Contact Us |
